MBX Biosciences, Inc. (MBX) Stock
MBX has an Alpha Score of 35 out of 100 (poor), computed on Nov 7, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported MBX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $22.18M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026.
What is MBX's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with weak momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own MBX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 402K | $22.18M | +541% |
| Millennium Management Israel Englander | 226K | $12.48M | -60% |
| D.E. Shaw David Shaw | 183K | $10.09M | -37% |
| Blackstone | 6K | $305.4K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are MBX Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 4, 26 | Azoulay Salomon | Chief Medical Officer | SELL | 373 | $20K |
| Aug 4, 26 | Azoulay Salomon | Chief Medical Officer | SELL | 370 | $24K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are MBX's key statistics?
Key statistics as of Nov 7, 2026
MBX price chart
Powered by TradingViewWhat does MBX Biosciences, Inc. do?
Mbx Biosciences Inc. is a biopharmaceutical company focused on the research and development of innovative endocrine therapeutics. It strives to address unmet medical needs through pioneering treatments for endocrine disorders. The company's central aim is to develop precision endocrinology therapies, leveraging proprietary technologies to create treatment options that are more precise and effective for specific patient populations. Mbx Biosciences operates at the intersection of biotechnology and healthcare, significantly impacting the health sector by working towards solutions that can transform the management of hormonal disorders. In terms of market significance, Mbx Biosciences represents the advancing frontier of personalized medicine, emphasizing targeted therapies that promise improved outcomes and quality of life for patients suffering from conditions related to hormonal imbalances. By contributing to the biopharmaceutical landscape with innovative solutions, it holds a vital role in advancing both the scientific understanding and therapeutic interventions in endocrine health.